Resectable Esophageal Cancer
7
1
2
2
Key Insights
Highlights
Success Rate
67% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 59/100
14.3%
1 terminated out of 7 trials
66.7%
-19.8% vs benchmark
0%
0 trials in Phase 3/4
50%
1 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (7)
Neoadjuvant Chemoimmunotherapy or Chemoradiotherapy in ESCC
Neoantigen Vaccine in Esophagus Cancer Patients Following Neoadjuvant Therapy and Surgical Resection
Evaluation, in Humans, of the Correlation Between Hepatotoxicity, Neurotoxicity Induced by Oxaliplatin, and Blood Levels of HMGB1
Avelumab With Chemoradiation for Stage II/III Resectable Esophageal and Gastroesophageal Cancer
Combination of Toripalimab and Neoadjuvant Chemoradiotherapy in Esophageal Cancer
Study of Combination of Cetuximab and Radiotherapy Added to the Standard Treatment for Oesophageal Adenocarcinoma
Circulating Tumor Cells as a Biomarker for Preoperative Prognostic Staging in Patients With Esophageal Cancer